The research involved 59 patients with moderate to severe depression who got either a high dose of psilocybin and a placebo, or escitalopram plus a dose of psilocybin so low as to be classed as non-active and unlikely to have an effect.
Dipatlisiso di akareditse balwetse ba le 59 ba ba nang le matshwao a a mo bogareng le a a kwa godimo a kgatelelo ya maikutlo, ba ba amogetseng melemo ya psilocybin le placebo, kgotsa escitalopram e e nang le psilocybin e e kwa tlase e e se kitlang e nna matswela.